PTAB 4 Years In: Biotech/pharma’s share of AIA trials increases
Biotechnology/pharmaceutical companies were slow to use the Patent Trial and Appeal Board. This is now changing, though this patent type has lower institution and invalidation rates
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: